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Abstract
 Background—West Nile virus (WNV) infection is mostly asymptomatic but 20% of subjects 
report WNV fever and 1% of patients experience neurological diseases with higher rates in elderly 
and immunosuppressed persons. With no treatment and no vaccine to prevent the development of 
symptomatic infections, it is essential to understand prognostic factors influencing symptomatic 
disease outcome. Host genetic background has been linked to the development of WNV 
neuroinvasive disease. The present study investigates the association between the ABO and Rh(D) 
blood group status and WNV disease outcome.
 Study Design and Methods—The distribution of blood groups was investigated within a 
cohort of 374 WNV+ blood donors including 244 asymptomatic (AS) and 130 symptomatic (S) 
WNV+ blood donors. Logistic regression analyses were used to examine associations between A, 
B, O and Rh(D) blood groups and WNV clinical disease outcome.
 Results—Symptomatic WNV+ donors exhibited increased frequencies of blood group A (S 
47.6% AS 36.8%, P=0.04, OR [95%CI] 1.56 [1.01–2.40]) and Rh(D)-negative individuals (S 
21.5% AS 13.1%, P=0.03, OR [95%CI] 1.82 [1.04–3.18]).
 Conclusion—The findings suggest a genetic susceptibility placing blood group A and Rh(D)-
negative individuals at risk for the development of symptomatic disease outcome after WNV 
infection.
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West Nile Virus (WNV) is a mosquito-borne flavivirus that was introduced to the US in 
1999 and is now the leading cause of arboviral encephalitis in the US.1 Over the past 17 
years, WNV has been responsible for more than 42,000 reported cases, of which 19,160 
presented with neuroinvasive disease, 22,434 with West Nile (WN) fever, and 1,7957 had a 
fatal outcome.2 Because WNV infection is asymptomatic in 80% of cases,1 these numbers 
underrepresent the overall frequency of infection. A recent study projected that over 3 
million persons have been infected with WNV in the US from 1999 to 2010, resulting in 
about 780,000 illnesses.3, 4
To date there is no treatment and no vaccine to prevent the development of symptomatic 
infections in humans.5 Therefore it is essential to understand the reasons for symptomatic 
outcome and prognostic factors influencing severe disease outcome to better manage 
patients care. Underlying risk factors associated with severe WNV disease are older age, 
hypertension,6 immunosuppression,7 and genetic factors. Indeed host genetic background 
such as mutations or deletions in the CCR5,8 IRF-3 and OAS1 genes,9 and host HLA class I 
alleles, such as the HLA-A*68 and C*08 alleles,10 have been linked to the development of 
WNV neuroinvasive disease. Research has begun to clarify the relationship between immune 
protection and disease,11 however the correlates of protective immunity in humans remain 
uncharacterized. It is, therefore, determinant to characterize aspects of the host-virus 
interaction to identify the host and viral parameters influencing WNV disease outcome.
Studies have suggested that WNV could bind to red blood cells (RBCs)12 and WNV RNA 
was found to persist longer in whole blood than in plasma.13, 14 The mechanisms underlying 
compartmentalization of WNV in the RBC fraction of the blood are unclear and the 
consequences on pathogenesis are unknown. RBCs are nonnucleated biconcave discs that 
contain hemoglobin and have no cellular machinery to synthesize de novo virions, it is 
therefore unlikely that WNV would be able to replicate in RBCs. However, reticulocytes 
constitute 1% of the circulating RBCs and could support WNV replication. With 
approximately five million RBCs per cubic millimeter in adults and the ability to access 
vascularized tissues through the smallest capillaries, RBCs represent potent vehicles for 
pathogens to be carried around the body.
RBCs harbor glycosylated antigens that include the ABO blood group antigens. Those result 
from the expression of inherited specific genes which code for glycosyltransferases whose 
sequential action builds the H, A, or B antigens. RBCs also carry other type of antigens such 
as the rhesus (Rh) antigens. Those are non-glycosylated hydrophobic transmembrane 
proteins that are integral proteins of the RBC membrane and assembled into a multimeric 
complex with other glycoproteins such as the Rh50 glycoprotein, 15 CD47, glycophorin B, 
Duffy, and LW.16
Various studies have reported the association between specific blood groups and 
susceptibility to particular diseases or manifestations of disease caused by bacterial, 
parasitic, and viral infections such as SARS CoV,17 V. cholerae,18–20 P.falciparum,21–24 
H.pylori and gastric ulcers or cancers,25–28 norovirus,29–32 rotavirus, dengue virus,33 and 
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hepatitis infections.34–36 The present study investigates the association between ABO and 
Rh(D) blood groups and WNV disease outcome in a cohort of 374 WNV+ blood donors.
 Materials and methods
 Study population
A total of 374 WNV+ subjects were enrolled in this study through the Blood Systems 
Research Institute (BSRI) between 2004 and 2011. Demographics such as age and gender 
were collected for all donors (Table 1). Race data were missing for 24 donors and available 
for 350 donors (298 Caucasian, 2 Black, 1 Asian, 40 Hispanic, and 9 donors from other race 
groups). All were enrolled by BSRI from the United Blood Services network after they 
tested positive for WNV RNA by routine donation screening (index). Infection was 
confirmed using follow-up samples showing seroconversion to anti-WNV IgM. Blood 
typing was performed by the blood bank at the time of donation. All of these donors were 
enrolled after signing an informed consent approved by the UCSF Committee on Human 
Research. Symptom questionnaires covering 12 possible WNV-related symptoms (fever, 
headache, eye pain, body aches, new skin rash, swollen lymph nodes, nausea or vomiting, 
muscle weakness, confusion, disorientation, memory problems, or other symptom) were 
administered at study enrollment and two weeks later. As previously described,37 a cutoff of 
four symptoms was used to categorized blood donors as asymptomatic (AS, number of 
reported symptoms < 4, n = 244) or symptomatic (S, number of reported symptoms ≥ 4, 
n=130) as previously used for pathogenesis studies10, 14, 38, 39. The average age was 47.4 
years for the WNV+ cohort, 48.2 years for asymptomatic, and 46 for symptomatic WNV+ 
donors (P AS vs. S = 0.15) (Table 1).
 Statistical analysis
The statistical package SAS was used for data analyses. Chi-square test of independence and 
Fisher Exact test were used to compare the demographic characteristics between 
asymptomatic and symptomatic WNV+ blood donors and to compare the distribution of 
blood groups within WNV+ blood donors and US blood donors.40
Multivariate logistic regression analyses were used to examine associations between A, B, O 
and WNV clinical disease outcome, adjusting for race and Rh(D) blood group status. 
Multivariate logistic regression analyses were used to examine associations between Rh(D) 
blood group status and WNV clinical disease outcome adjusting for race. For statistical 
presentation, instead of using a reference group, each group is compared to all other donors 
(A versus non-A, O versus non-O, Rh(D)-negative versus Rh(D)-positive, etc.). Statistical 
significance was determined at P < 0.05. False discovery rates (FDR) were calculated by 
PROC MULTITEST (SAS 9.3). FDR-controlling procedures are designed to control the 
probability of Type I errors in analyses with multiple cmparisons. FDR<0.1 would support 
the signficance of P-values while FDR>0.1 would indicate that caution needs to be applied 
when analyzing the signficance of the findings.
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 WNV+ blood donors have the same blood type distribution as the general blood donor 
population
Demographics and blood type data were collected for the 374 WNV+ blood donors included 
in this analysis (Table 1). This cohort consisted of 79.7% White non-Hispanic Caucasians, 
10.7% Hispanics, 0.5% Blacks, 0.3% Asians, and 2.4% others with race data missing for 
6.4% of the subjects. The cohort had 56.7% of males and 43.3% of females. The mean age 
was 47.4 years.
The frequencies of subjects with O, A, B, AB, RhD-positive, and RhD-negative blood types 
were calculated for the whole cohort. The blood type distribution within the WNV+ cohort 
was the same as within the general blood donor population in the US,40 with a majority of O 
(45.5%), then A (40.6%), then B (10.2%), a minority of AB (3.7%), and 84% of Rh(D)-
positive versus 16% of Rh(D)-negative subjects (Table 2).
 A and Rh(D)-negative blood groups are associated with symptomatic WNV disease 
outcome
Symptom questionnaires were analyzed as previously described,10, 37, 39 and revealed that 
130 of the 374 WNV+ blood donors included in this cohort developed four or more 
symptoms during the three week period around index donation and could be categorized as 
symptomatic (S) while 244 subjects remained asymptomatic (AS). No significant difference 
was found in the demographic characteristics of asymptomatic and symptomatic WNV+ 
blood donors included in this analysis (Table 1). Asymptomatic and symptomatic WNV+ 
blood donors in this study did not have significant difference of mean age (48.2 and 46 
years, respectively, P = 0.15).
The frequencies of O, A, B, AB, Rh(D)-positive, and Rh(D)-negative blood groups were 
calculated within 244 asymptomatic and 130 symptomatic WNV+ blood donors. The 
distribution of blood groups was compared between asymptomatic and symptomatic WNV+ 
blood donors and a higher frequency of blood group A subjects was found within 
symptomatic than within asymptomatic WNV+ blood donors (47.6% in S vs. 36.8% in AS, 
P = 0.04) (Table 2). The odds ratio of symptomatic WNV disease outcome among blood 
donors with blood group A was significantly higher than within blood donors with blood 
group O (OR [95%CI] = 1.56 [1.01, 2.40]). A higher frequency of Rh(D)-negative subjects 
was found within symptomatic WNV+ blood donors (21.5% in S vs. 13.1% in AS, P = 
0.03). The odds ratio of symptomatic WNV disease outcome among Rh(D)-negative blood 
donors was significantly higher than within Rh(D)-positive blood donors (OR[95%CI] = 
1.82 [1.04, 3.18]) (Table 2, unadjusted P-values obtained using the Chi-square test of 
independence).
Previous studies have reported the highest percentages of Rh(D)-negative subjects are 
present in the white non-Hispanic race group.40 A multivariate logistic regression analysis 
was used to adjust for race, the association between blood group A and symptomatic WNV 
disease outcome persisted after adjustment for both Rh(D) status and race (P S vs. AS = 
0.02, OR [95%CI] = 1.70 [1.08, 2.66]) and the association between Rh(D)-negativity and 
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symptomatic WNV disease outcome persisted after adjustment for race (P S vs. AS = 0.02, 
OR [95%CI] = 1.96 [1.1, 3.48]). Therefore A and Rh(D)-negative blood groups are 
independently associated with symptomatic WNV disease outcome and this association 
persisted after controlling for race (Table 2, adjusted P-values obtained by multivariate 
logistic regression adjusting for race).
Therefore, blood group A and Rh(D)-negativity could represent potential risk factors 
associated with symptomatic WNV clinical outcome.
Within Rh(D)-positive WNV+ blood donors, the frequency of blood group A individuals 
within symptomatic WNV+ blood donors was higher but not significantly higher than within 
asymptomatic WNV+ blood donors (P = 0.33) though blood group A was significantly 
associated with symptomatic WNV disease outcome after adjustment for Rh(D) and race 
status (P = 0.02, OR [95%CI] = 1.70 [1.08, 2.66]). Within Rh(D)-positive WNV+ blood 
donors, the frequency of blood group B individuals within symptomatic WNV+ blood 
donors was significantly lower than within asymptomatic WNV+ blood donors (P = 0.002, 
OR[95%CI] = 0.27 [0.11,0.65]) suggesting a potential association between B/Rh(D)-positive 
(B+) blood groups though blood group B was not significantly associated with 
asymptomatic WNV disease outcome after adjustment for Rh(D) status (P = 0.32).
Within Rh(D)-negative WNV+ blood donors, the frequency of blood group A individuals 
within symptomatic WNV+ blood donors was significantly higher than within asymptomatic 
WNV+ blood donors (P = 0.03) and the odds of developing symptomatic disease for A/
Rh(D)-negative (A−) (OR[95%CI] =2.33 [1.04,5.20]) was even higher than for blood group 
A (OR[95%CI] =1.56 [1.01, 2.40]) or Rh(D)-negative individuals (OR[95%CI] = 1.82 
[1.04,3.18]) suggesting a cumulative effect when both risk factors were combined. Within 
Rh(D)-negative WNV+ blood donors, the frequency of blood group B individuals within 
symptomatic WNV+ blood donors was higher than within asymptomatic WNV+ blood 
donors (P = 0.04 OR[95%CI] = 3.88 [0.95, 15.8]) suggesting the protective role of blood 
group B is lower than the risk associated with Rh(D)-negative blood group.
 The frequency of blood group A subjects is higher in the symptomatic WNV+ blood 
donor population than in the healthy US blood donor population
When the WNV+ blood donor population was compared to the US blood donor population, 
the frequency of Rh(D)-negative subjects was significantly higher within symptomatic WNV
+ blood donors than within the US blood donor population (21.5% for S vs. 14.6% for US 
blood donors, P = 0.03, OR[95%CI] = 1.61 [1.06–2.44]) (Table 3, upper part) but the 
difference was not statistically significant when the analysis was restricted to white non-
Hispanic individuals (22.7% for S vs. 17.3% for US blood donors, P = 0.13) (Table 3, lower 
part) suggesting that race may be a confounder factor. Indeed, there was a higher frequency 
of white non-Hispanic individuals within the symptomatic WNV+ population than within 
the US blood donor population (84.6% within S WNV+ donors vs. 71.7% within US blood 
donors, P = 0.0007).
However, there was an over-representation of blood group A subjects within symptomatic 
WNV+ blood donors compared to the US blood donor population (47.6% within S WNV+ 
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donors vs. 37.1% within US blood donors, P = 0.01, OR[95%CI] = 1.55 [1.10–2.18]) (Table 
3, upper part) and this difference persisted when the analysis was restricted to white non-
Hispanic individuals (49.1% within S WNV+ donors vs. 39.7% within US blood donors, P = 
0.05, OR[95%CI] = 1.46 [1.01–2.13]) (Table 3, lower part). The frequency of blood group A 
individuals was also higher within symptomatic WNV+ Rh(D)-positive blood donors than 
within the US Rh(D)-positive blood donor population (47.1% within S WNV+ donors vs. 
36.9% within US blood donors, P = 0.03, OR[95%CI] = 1.52 [1.03–2.24]) (Table 3, upper 
part). Therefore, blood group A individuals are more common within symptomatic WNV+ 
donors than within the healthy US blood donor population.
 Discussion
While race, gender, and age were not associated with WNV disease outcome in this cohort, 
blood group A was found at higher frequency in symptomatic than in asymptomatic WNV+ 
donors. Rh(D)-negativity was also more frequent in symptomatic than in asymptomatic 
WNV+ donors. The data suggest an association between blood groups and WNV disease 
outcome, with blood group A and Rh(D)-negativity being risk factors for the development of 
symptomatic WNV disease outcome. When the distribution of blood groups was compared 
within the WNV+ donor population and within the US blood donor population using the 
numbers previously reported by Garratty et al., an increased frequency of blood group A 
individuals was found within symptomatic WNV+ donors than within the US blood donor 
population40.
While the comparison of blood group distribution within WNV+ groups experiencing 
different disease outcomes (asymptomatic versus symptomatic) is straightforward, the 
comparison of blood group distribution within WNV+ donor population and US blood donor 
population is interesting but limited. Indeed, comparing blood group distribution within 
WNV+ blood donor population enrolled by Blood Systems Inc. from 2004 to 2011 to blood 
group distribution as reported by Garratty et al. within US blood donors enrolled at five 
other blood centers between 1991 and 200040 may be biased by donor stratification resulting 
from collection based on blood group need that would potentially change over different 
period of time and geographic areas. Therefore, the comparison between blood group 
distribution within the WNV+ donor population and within the US blood donor population 
is worth reporting but the key findings are more related to the differences of blood group 
distribution identified within symptomatic versus asymptomatic WNV+ donors which would 
not be impacted by blood group recruitment biase.
In a previous study, higher WNV viral loads were observed over the three months post-index 
in blood group A WNV+ subjects than in blood group O WNV+ subjects.14 This was not the 
case for Rh(D)-negative donors, suggesting the mechanisms that underlie the association 
between blood group A and WNV disease outcome are different from the ones underlying 
the association between blood group Rh(D)-negative and WNV disease outcome. From an 
evolutionary stand point, it is however interesting to note that the frequency of Rh(D)-
negative individuals is higher in white non-Hispanic, than in African, and Asian 
populations.40 Therefore the world distribution of Rh(D)-negative humans is concentrated in 
geographic areas where WNV outbreaks have been documented for the increased severity of 
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symptoms, as reported in the 90’s around the Mediterranean’s, and since 1999 in North 
America. WNV was first isolated in 1937 in Uganda from a women with fever and studies 
have documented the widespread distribution of WNV in Africa through seroprevalence 
studies conducted in the 50’s and revealing a high frequency of young adults immunized 
during childhood.42 The symptoms associated with WNV infection seemed more severe 
after WNV introduction in North America. Whether this is due to virus and human co-
evolution and immunization earlier during childhood in endemic areas, or underreporting of 
more severe symptoms is unclear but it is worth to note that the frequency of Rh(D)-negative 
subjects is the highest in Causian populations of Europe and North America and the lowest 
in the Asian population where WNV infection remains unnoticed.
Numerous studies have been published to date on the association between blood groups and 
diseases.43, 44 However, most studies are based on statistical analyses and some are limited 
by sample size, racial heterogeneity, methodological approaches.45 Therefore it is important 
to reproduce the findings in different cohorts. Noteworthy, similar results were recently 
presented by Politis et al.46 Indeed, an association was reported between increased 
frequencies of blood group A and Rh(D)-negative individuals within 132 patients previously 
infected with lineage 2 WNV in Greece compared to healthy blood donors from the same 
WNV affected areas. This is supporting the findings of the present study.
The body of literature reporting an association between blood groups and diseases is 
growing. Some studies have clearly established the association between blood group O and 
reduced risk of severe malaria, with the theory that Plasmodium falciparum could have 
exerted a selective pressure on the human population in favor of individuals with blood 
group O in malaria-endemic regions.22 The mechanisms underlying the association between 
blood groups and malaria outcome are unclear but reports have suggested that blood group 
A antigen could serve as a co-receptor for Plasmodium falciparum,21 potentially explaining 
the association between blood group A and severe malaria.22 It was also recently reported 
that human macrophages have a higher avidity for Plasmodium falciparum-infected O 
erythrocytes than for Plasmodium falciparum-infected A or B erythrocytes and therefore 
subjects with blood group O might have accelerated parasite clearance compared to others.24 
In the present study, similar mechanisms could underlie the association between blood group 
A and symptomatic WNV disease. Indeed, it was shown that WNV interacts with LBP and 
αVβ3 integrin at the cell surface of host cells through its E glycoprotein,47, 48 and blood 
group A antigen could serve as a co-receptor for WNV. This would explain the findings that 
subjects with blood group A demonstrated higher viral loads in whole blood than subjects 
with other blood groups,14 however, this would not explain why the same assoication is not 
observed for subjects with blood group AB, whose erythrocytes express approximately half 
of the number of A sites than A erythrocytes49 and this would not explain the association 
with Rh(D)-negativity. An alternative hypothesis would be that other glycosylated structures 
expressed differentially at the surface of erythrocytes from blood group A and Rh(D)-
negative donors would facilitate WNV binding through glycan-glycan or lectin-glycan 
interactions in a Velcro-like interaction or would serve as receptors or co-receptors. While 
the potential mechanisms underlying such associations have been previously hypothesized 
and discussed,14 further investigation is needed to clearly understand the association 
between blood group and WNV pathogenesis.
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The present study suggests an association between blood groups and WNV pathogenesis 
with A and Rh(D)-negative blood groups being potential new risk factors for the 
development of symptoms after WNV infection. This study adds to our previous report of 
WNV RNA persisting at higher levels in whole blood from blood group A WNV+ 
individuals. The findings reported in the present study are based on the statistical analysis of 
epidemiologic data collected from a cohort of individuals infected with lineage 1 WNV and 
are strengthened by the findings obtained on a different cohort of individuals infected with 
lineage 2 WNV.46 Therefore the present findings support the interest in further pursuing the 
investigation of the mechanisms underlying the association between blood group A and 
Rh(D)-negativity and symptomatic WNV disease outcome.
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